Pfizer and BioNTech requested regulatory agencies expand Emergency Use of COVID-19 vaccine to adolescents
On Apr. 9, 2021, Pfizer announced they had requested amendments to the U.S. Emergency Use Authorization (EUA) of…
-
-
Antiviral drug Favipiravir investigated as a possible COVID-19 treatment for at-home recovery in PRINCIPLE trial
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
-
ImmunityBio announced single prime hAd5 COVID-19 vaccination induced 10-fold increase in T cell response
On Apr. 8, 2021, ImmunityBio reported initial data indicating that a single subcutaneous injection of the companyﾒs COVID-19…
-
Lilly and Incyte phase 3 COV-BARRIER study of baricitinib in COVID-19 patients did not meet endpoint
On Apr. 8, 2021, Eli Lilly and Incyte announced results of COV-BARRIER, a Phase 3 study evaluating baricitinib…
-
CDC awarded $3 billion to expand COVID-19 vaccine programs
On Apr. 7, 2021, the Centers for Disease Control and Prevention (CDC) announced it had awarded $3 billion…
-
WHO Global Advisory Committee on Vaccine Safety reported on AstraZeneca COVID-19 vaccine
On Apr. 7, 2021, the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) announed…
-
NIH began study of allergic reactions to Moderna, Pfizer-BioNTech COVID-19 vaccines
On Apr. 7, 2021, the National Institutes of Health (NIH) announced that a clinical trial was underway to…
-
McGill University researchers developed innovative tough gel sheathed (TGS) sutures inspired by the human tendon
On Apr. 7, 2021, McGill University researchers announced that they had developed an innovative tough gel sheathed (TGS)…
-
Moderna announced publication of antibody persistence data of its COVID-19 vaccine in the NEJM
On Apr. 7, 2021, Moderna announced publication of antibody persistence data out to 6 months following the second…
-
AIM ImmunoTech announced positive data in phase 1 study Investigating intranasal administration of Ampligen as potential treatment for COVID-19
On Apr. 7, 2021, AIM ImmunoTech announced that it had completed dosing of Cohort 1 in a Phase…
-
Nearly 80 percent of teachers, school staff, and childcare workers received at least one shot of COVID-19 vaccine
On Apr. 6, 2021, the Centers for Disease Control and Prevention (CDC) reported that nearly 80 percent of…
-
Moderna and Catalent announced long-term strategic collaboration for vial filling of COVID-19 vaccine
On Apr. 6, 2021, Moderna and Catalent announced the expansion of their strategic collaboration to dedicate a new…
-
Innovation Pharma announced increased dosing in phase 2 clinical trial of Brilacidin in COVID-19 patients
On Apr. 5, 2021, Innovation Pharmaceuticals announced that an independent Data Monitoring Committee (DMC) completed its scheduled review…
-
Anixa Biosciences and OntoChem entered next stage of development for Covid-19 therapeutic
On Apr. 5, 2021, Anixa Biosciences announced that based on Proof of Concept animal study results, it was…
-
Novavax initiated COVID-19 vaccine clinical trial crossover
On Apr. 5, 2021, Novavax announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373,…
-
Positive phase 1/2 results reported for Valneva’s inactivated COVID-19 vaccine candidate using CpG 1018ﾙ adjuvant
On Apr. 5, 2021, Dynavax Technologies announced that Valneva had reported positive initial results for Part A of…
-
The FDA issued an EUA to Symbiotica for the COVID-19 self-collected antibody test system
On Apr. 5, 2021, the FDA issued an Emergency Use Authorization (EUA) to Symbiotica for the COVID-19 Self-Collected…
-
Emergent announced support of manufacturing capacity expansion for Johnson & Johnson’s COVID-19 vaccine
On Apr. 4, 2021, Emergent BioSolutions announced it had received a contract modification to increase the original task…
-
Emergent announced topline data from NIAID phase 3 ITAC Trial evaluating immunoglobulins as treatment for patients with COVID-19
On Apr. 2, 2021, Emergent BioSolutions announced that topline data from the ITAC trial had demonstrated that the…
-
Arbutus Biopharma, X-Chem and Proteros biostructures entered into pan-coronavirus discovery research and license agreement
On Apr. 1, 2021, Arbutus Biopharma, X-Chem and Proteros Biostructures announced hat they had entered into a discovery…
-
Pfizer and BioNTech confirmed high efficacy and no serious safety concerns in updated COVID-19 vaccine study
On Apr. 1, 2021, Pfizer and BioNTech announced updated topline results from analysis of 927 confirmed symptomatic cases…
-
Moderna provided storage update and FDA authorization for 15-doses per vial of COVID-19 vaccine
On Apr. 1, 2021, Moderna announced that based on submitted stability data, the U.S. Food and Drug Administration…
-
BD received EUA for asymptomatic screening for SARS-CoV-2 through Serial Rapid Antigen Testing
On Apr. 1, 2021, BD (Becton, Dickinson) announced the U.S. Food and Drug Administration (FDA) had granted Emergency…
-
COVID-19 variant vaccine trial began at KPWHRI
On Apr. 1, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that an investigational vaccine designed to…
-
FDA revised Moderna COVID-19 vaccine EUA to increase the number of vaccine doses available
On Apr. 1, 2021, the U.S. Food and Drug Administration (FDA) announced two revisions regarding the number of…
-
Risk of severe Covid-19 from asthma and other respiratory diseases modestly increased
On Apr. 1, 2021, Oxford University scientists announced they had published in The Lancet Respiratory Medicine, a study…
-
Pfizer-BioNTech announced positive topline results of pivotal COVID-19 vaccine study in adolescents
On Mar. 31, 2021, Pfizer and BioNTech announced that, in a Phase 3 trial in adolescents 12 to…
-
Biotechnology | COVID-19 | FDA
Quidel’s QuickVue At-Home OTC COVID-19 Test received EUA for screening use with serial testing
On Mar. 31, 2021, Quidel announced that it had received an Emergency Use Authorization (EUA) from the FDA,…
-
NIH clinical trial evaluating Moderna COVID-19 variant vaccine began
On Mar. 31, 2021, the National Institutes of Health (NIH) announced that an investigational vaccine designed to protect…
-
CytoDyn’s leronlimab decreased mortality at 14 days by 82% amongst critically Ill COVID-19 patients
On Mar. 30, 2021, CytoDyn announced further results from its CD12 trial of severe-to-critically ill patients with COVID-19….
